Lantern Pharma (LTRN) Earnings Analysis

Lantern Pharma (LTRN) next reports earnings on 2026-08-12, consensus EPS -0.38 USD. Last quarter (2026-05-15) it beat with EPS -0.3 USD vs -0.36 USD est (+16.7%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -1.96.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does LTRN next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.38 USD
Revenue estimaten/a

LTRN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.3 USD-0.36 USD+16.7%Beat
2026-03-30-0.36 USD-0.46 USD+21.7%Beat
2025-08-13-0.4 USD-0.53 USD+24.5%Beat
2025-05-15-0.42 USD-0.49 USD+14.3%Beat
2024-11-07-0.42 USD-0.56 USD+25%Beat
2024-08-08-0.46 USD-0.55 USD+16.4%Beat

Beat rate: 6/6 (100%) over reported quarters with consensus data.

LTRN valuation and analyst view

Trailing P/E-1.96
Trailing EPS-1.414 USD
Price / book9.27
Dividend yield0.00%
Market cap0.04B
Analyst consensusBuy (2 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Lantern Pharma (LTRN)'s next earnings date?

Lantern Pharma is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.38 USD.

Did LTRN beat earnings last quarter?

In its 2026-05-15 report, LTRN posted EPS of -0.3 USD versus a -0.36 USD estimate — a beat of 16.7%.

What is LTRN's earnings track record?

Over the last 6 reported quarters with consensus data, LTRN beat estimates 6 times (100%).

What is LTRN's current P/E ratio and EPS?

LTRN trades at a trailing P/E of -1.96 on trailing EPS of -1.414003695004812 USD.

What do analysts rate LTRN?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell).